Navigating Novel Pathways and Treatment Decisions in IgA Nephropathy - Episode 7
Trials of B-cell therapies reported low infection rates, yet real-world experience is still limited. Dr. Geara describes baseline screening and immunoglobulin monitoring, while Dr. Cheung argues the benefit extends to most patients regardless of proteinuria or eGFR.
Dr. Wadhwani asks Dr. Geara how he evaluates the safety of B-cell-targeted biologics and what he prioritizes when counseling patients. Dr. Geara says efficacy looks similar across the agents and the safety profile appears favorable. He reminds viewers that many phase 2 and 3 studies enrolled during the COVID-19 pandemic, yet the rates of infection and serious infection stayed low. At the same time, these are new agents, so real-world safety experience is very limited.
He notes that trials screened participants for infections and checked immunoglobulin levels before enrollment. In his own practice, he checks immunoglobulin levels at baseline and every three months. The patients he has treated so far have not shown major problems, and in the trials, decreases were managed by holding the medication. He also recommends evaluating for latent infection before starting therapy. Safety looks reassuring, he says, but clinicians must keep monitoring every patient because unexpected issues could emerge as use broadens.
Dr. Wadhwani agrees that trial settings differ from real-world practice. The community will need protocols for long-term monitoring and for deciding when to intervene, assuming the low infection risk holds.
She then asks Dr. Cheung which patients are appropriate candidates. Dr. Cheung favors a holistic view that includes progression rate before and after diagnosis, kidney biopsy findings, and proteinuria levels. Still, the trial data suggest APRIL and BAFF/APRIL modulators benefit patients across a wide range of proteinuria and eGFR. Those factors did not appear to alter response, so Dr. Cheung would consider the class for most patients.
The next episode in this series, "Choosing and Sequencing IgAN Therapies: Oral Agents, Biologics, and Combinations," features the panel on oral versus injectable options, sequencing, and whether combination therapy is coming.